NCT04503629View on ClinicalTrials.gov

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

May 17, 2019

Study Completion Date

May 17, 2019

Conditions

Duodenal Ulcer，DU

Interventions

DRUG

Anaprazole Sodium

Anaprazole Sodium 20mg

DRUG

Anaprazole Sodium

Anaprazole Sodium 40mg

DRUG

Rabeprazole sodium

Rabeprazole sodium 10mg

Trial Locations (1)

330006

The Fisrst Affiliated Hospital of NanChang University, Nanchang

All Listed Sponsors

lead

Sihuan Pharmaceutical Holdings Group Ltd.

INDUSTRY

NCT04503629 - A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. | Biotech Hunter | Biotech Hunter